Prelude Therapeutics Incorporated
PRLD
$5.55
$0.193.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -34.05% | 36.90% | 16.57% | 36.84% | 2.66% |
| Total Depreciation and Amortization | -9.72% | -6.46% | -1.65% | -1.85% | -0.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.25% | -2.01% | -26.01% | -30.80% | -7.24% |
| Change in Net Operating Assets | 69.98% | -136.88% | 1,543.16% | -448.04% | 110.75% |
| Cash from Operations | 28.18% | -193.80% | 220.95% | 26.69% | 23.83% |
| Capital Expenditure | -- | -- | -- | 100.00% | 57.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -870.71% | 114.09% | -250.51% | 247.38% | -81.46% |
| Cash from Investing | -870.71% | 114.09% | -250.51% | 247.98% | -81.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 65.81% |
| Issuance of Common Stock | 290,867.74% | -99.88% | -- | -100.00% | -- |
| Repurchase of Common Stock | 74.51% | -920.00% | 0.00% | -150.00% | 60.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,385.37% | -- | -- | -- | -- |
| Cash from Financing | 27,431.21% | -101.26% | 498,980.00% | -113.51% | 123.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 135.13% | -9.97% | -158.54% | 244.46% | -152.23% |